Iluzanebart for leukoencephalopathies

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trials ended early. Its trials were stopped early. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Dec 2022: Trial started, NCT05677659
  2. 10 Jan 2023: Trial registered, NCT05677659
  3. 4 Jun 2025: Trial terminated, NCT05677659

The trials

NCT05677659: A Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia

State
Stopped early
Phase
Phase 2
People
20 taking part
Started
14 Dec 2022
Primary completion
14 Feb 2025
Arms
VGL101
Results
None posted
  1. 14 Dec 2022: Trial started
  2. 10 Jan 2023: Trial registered
  3. 4 Jun 2025: Trial terminated

How the status changed

  1. 19 Nov 2026: First set: Trials ended early

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.